Description
Immunohistochemistry (IHC) test for PD-L1 expression using specific antibodies (22C3, SP142, SP263). Used to determine eligibility for immunotherapy with PD-1/PD-L1 inhibitors in cancers like non-small cell lung cancer (NSCLC).
This lab test includes home sample collection via a provided kit or by a clinician, and you'll receive a comprehensive physical health report with your results.